CRISPR Therapeutics AG (CRSP)

100.96 +0.12  +0.12% NASDAQ May 13, 16:59 USD
View Full Chart
Price Chart
View All CRSP News


View All Events


Date Type Description
07/27/2021 00:00 Earnings Results Q2 2021 Earnings Results
04/27/2021 00:00 Earnings Results Q1 2021 Earnings Results
02/16/2021 00:00 Earnings Results Q4 2020 Earnings Results
10/28/2020 00:00 Earnings Results Q3 2020 Earnings Results
07/27/2020 00:00 Earnings Results Q2 2020 Earnings Results
06/11/2020 14:00 EDT AGM 2019 Annual General Meeting
View All Performance Charts

Total Returns Comparison

Ratings & Reports



  • Description: CRISPR Therapeutics AG is a gene-editing company. It is engaged in the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 is a technology that allows for precise, directed changes to genomic DNA. The company advanced programs target beta-thalassemia and sickle cell disease, two hemoglobinopathies that have a high unmet medical need.
  • URL:
  • Investor Relations URL:
  • HQ State/Province: N/A
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Mid Cap/Blend
  • Next Earnings Release: Jul. 27, 2021
  • Last Earnings Release: Apr. 27, 2021
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A

Top Fund Holders

Symbol Name Weighting
GNOM Global X Genomics & Biotechnology ETF 3.95%
NEXTX Shelton Green Alpha 3.56%
MID326 Global Healthcare Div F 3.45%
IMPLX ERShares US Large Cap Fund™ Inst 3.18%
IDNA iShares Genomics Immnlgy & Hlthcr ETF 2.96%
EARK.NO Emerge ARK Global Disruptive Innovt ETF 2.82%
ADNRX American Beacon ARK Transfmt Innov R6 2.63%
ARKK ARK Innovation ETF 2.47%
ARKG ARK Genomic Revolution ETF 2.35%
BBH VanEck Vectors Biotech ETF 2.02%
IMPAX ERShares US Small Cap Fund™ Inst 1.75%
RYCFX Rydex Biotechnology C 1.62%





Please note that this feature is only available as an add-on to YCharts subscriptions.

Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{}} No credit card required.

Already a subscriber? Sign in.